Novavax Stock Today
| NVAX Stock | USD 7.99 0.18 2.20% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Novavax is trading at 7.99 as of the 16th of March 2025; that is 2.2 percent decrease since the beginning of the trading day. The stock's open price was 8.17. Novavax has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of December 1995 | Category Healthcare | Classification Health Care |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. The company has 160.84 M outstanding shares of which 35.45 M shares are now shorted by private and institutional investors with about 9.02 trading days to cover. More on Novavax
Moving together with Novavax Stock
Moving against Novavax Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Novavax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Stanley Erck | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNovavax can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novavax's financial leverage. It provides some insight into what part of Novavax's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Novavax (NVAX) is traded on NASDAQ Exchange in USA. It is located in 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 and employs 952 people. Novavax is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B. Novavax conducts business under Biotechnology sector and is part of Health Care industry. The entity has 160.84 M outstanding shares of which 35.45 M shares are now shorted by private and institutional investors with about 9.02 trading days to cover.
Novavax currently holds about 1.28 B in cash with (87.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Novavax Probability Of Bankruptcy
Ownership AllocationNovavax maintains a total of 160.84 Million outstanding shares. Over half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novavax Ownership Details
Novavax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-12-31 | 1.4 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.4 M | |
| Tsp Capital Management Group/llc | 2024-12-31 | 1.4 M | |
| Sg Americas Securities, Llc | 2024-12-31 | 1.2 M | |
| Citigroup Inc | 2024-12-31 | 1 M | |
| Millennium Management Llc | 2024-12-31 | 1 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 957.7 K | |
| Jane Street Group Llc | 2024-12-31 | 951.9 K | |
| Citadel Advisors Llc | 2024-12-31 | 853.5 K | |
| Vanguard Group Inc | 2024-12-31 | 15.7 M | |
| Blackrock Inc | 2024-12-31 | 13.5 M |
Novavax Historical Income Statement
Novavax Stock Against Markets
Novavax Corporate Management
| Mark Casey | Chief VP | Profile | |
| JD Esq | Senior Officer | Profile | |
| Robert MD | Senior Officer | Profile | |
| Ian Watkins | Executive Officer | Profile |
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.